A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene
Graciela Kuperstein1, Elaine Jack, Steven A Narod
1The Centre for Research in Women's Health, University of Toronto, Toronto, Ontario, Canada.
Genetic Testing
|March 21, 2006
Summary
A new fluorescent multiplex denaturing gradient gel electrophoresis (FMD) technique effectively screens for BRCA1 gene mutations and polymorphisms. This accurate and efficient method aids in detecting variants in numerous small exons and splice sites, crucial for cancer research.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- BRCA1 gene mutation screening is complex due to the gene's size and mutation diversity.
- Exon 11 is typically screened using protein truncation tests (PTT).
- A need exists for efficient screening of other BRCA1 exons and splice sites.
Purpose of the Study:
- To develop and validate a novel fluorescent multiplex denaturing gradient gel electrophoresis (FMD) technique.
- To screen numerous small exons and splice sites of the BRCA1 gene.
- To assess the utility of FMD for detecting BRCA1 variants in ovarian cancer patients.
Main Methods:
- Multiplex polymerase chain reaction (PCR) amplification of target BRCA1 regions.
- Denaturing gradient gel electrophoresis (DGGE) for amplicon separation.
- Wet gel scanning for immediate result acquisition.
Main Results:
- The FMD technique successfully detected all variants in 16 test samples across 12 BRCA1 exons.
- Screening of 188 ovarian cancer patient samples identified 22 new sequence variants (11.7%) and 243 polymorphisms.
- Detected variants included single nucleotide substitutions, deletions, and insertions.
Conclusions:
- FMD offers an accurate, rapid, nonradioactive, and cost-efficient method for BRCA1 gene scanning.
- The technique demonstrates high sensitivity and ease of interpretation.
- FMD is a valuable tool for mutation and polymorphism detection in BRCA1, supporting research and epidemiological studies.
